Fremanezumab for the Preventive Treatment of Chronic Migraine

Fremanezumab, an anti-CGRP antibody, given subcutaneously monthly or quarterly, resulted in significantly fewer headache days than placebo in a 12-week trial involving patients with chronic migraine. Migraine-specific quality of life was significantly higher with fremanezumab.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2017-11, Vol.377 (22), p.2113-2122
Hauptverfasser:	Silberstein, Stephen D, Dodick, David W, Bigal, Marcelo E, Yeung, Paul P, Goadsby, Peter J, Blankenbiller, Tricia, Grozinski-Wolff, Melissa, Yang, Ronghua, Ma, Yuju, Aycardi, Ernesto
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Calcitonin Calcitonin gene-related peptide Calcitonin Gene-Related Peptide Receptor Antagonists Chronic Disease Clinical trials Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Drug therapy Female Headache Headaches Humans Injection Injections, Subcutaneous Least-Squares Analysis Male Middle Aged Migraine Migraine Disorders - prevention & control Monoclonal antibodies Pain Preventive medicine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Fremanezumab, an anti-CGRP antibody, given subcutaneously monthly or quarterly, resulted in significantly fewer headache days than placebo in a 12-week trial involving patients with chronic migraine. Migraine-specific quality of life was significantly higher with fremanezumab.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1709038